Mangoceuticals
MGRX
13 hedge funds and large institutions have $320K invested in Mangoceuticals in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
117% more funds holding
Funds holding: 6 → 13 (+7)
117% more capital invested
Capital invested by funds: $148K → $320K (+$172K)
2.59% more ownership
Funds ownership: 1.95% → 4.54% (+2.6%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Ackerman Capital Advisors
Dallas,
Texas
|
+$275K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.3K |
| 3 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
+$27K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$11.9K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$9.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$41.2K |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
-$30.4K |
| 3 |
VF
Virtu Financial
New York
|
-$25.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16.1K |
| 5 |
Morgan Stanley
New York
|
-$3.15K |
MGRX Hedge Fund Activity: Q3 2024 in Review
13 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q3 2024, worth a combined $320K — up 117% from $148K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MGRX positions and 4 closed out — a net gain of 7 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Ackerman Capital Advisors, opening a new position worth an estimated $275K. The largest seller was Citadel Advisors, exiting entirely with an estimated $41.2K sold.
- 13 institutional investors held Mangoceuticals (MGRX) as of Q3 2024, up from 6 in Q2 2024.
- Funds reported $320K of Mangoceuticals stock for Q3 2024, up 117% quarter-over-quarter.
- 11 funds opened new Mangoceuticals positions in Q3 2024 and 4 closed out, a net change of +7 holders.
- The largest Mangoceuticals buyer in Q3 2024 was Ackerman Capital Advisors, an estimated $275K added.
- The largest Mangoceuticals seller in Q3 2024 was Citadel Advisors, an estimated $41.2K sold.
Based on aggregated 13F filings for Q3 2024.